Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 2, 2011, Pages 144-155

  Chemaly, Elie R ^a   Hadri, Lahouaria ^a   Zhang, Shihong ^a   Kim, Maengjo ^a,b   Kohlbrenner, Erik ^a   Sheng, Jipo ^a   Liang, Lifan ^a   Chen, Jiqiu ^a   K Raman, Purushothaman ^a   Hajjar, Roger J ^a   Lebeche, Djamel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adeno associated virus 9; Apoptosis; Cardiac remodeling; Diabetic cardiomyopathy; Fibrosis; Hemodynamics; Oxidative stress; Resistin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; GLUCOSE; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; PHOSPHOLAMBAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESISTIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CARDIOMYOPATHY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELLS, CULTURED; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART; HEART VENTRICLES; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION MEDIATORS; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RESISTIN; VENTRICULAR REMODELING;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 9; ANIMALIA; RATTUS;

EID: 79959493241     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.04.006     Document Type: Article

References (44)

1. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
2. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182(2):241-248.
3. Wang B.W., Hung H.F., Chang H., Kuan P., Shyu K.G. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2007, 293(4):H2305-H2312.
4. Karakikes I., Kim M., Hadri L., Sakata S., Sun Y., Zhang W., et al. Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. PLoS One 2009, 4(7):e6474.
5. Gualillo O., Gonzalez-Juanatey J.R., Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007, 17(8):275-283.
6. Gao J., Chang Chua C., Chen Z., Wang H., Xu X., Hamdy R.C., et al. Resistin, an adipocytokine, offers protection against acute myocardial infarction. J Mol Cell Cardiol 2007, 43(5):601-609.
7. Rothwell S.E., Richards A.M., Pemberton C.J. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006, 349(1):400-407.
8. Frankel D.S., Vasan R.S., D'Agostino R.B., Benjamin E.J., Levy D., Wang T.J., et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009, 53(9):754-762.
9. Kim M., Oh J.K., Sakata S., Liang I., Park W., Hajjar R.J., et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008, 45(2):270-280.
10. Suckau L., Fechner H., Chemaly E., Krohn S., Hadri L., Kockskamper J., et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009, 119(9):1241-1252.
11. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
12. Gueret P., Meerbaum S., Zwehl W., Wyatt H.L., Davidson R.M., Uchiyama T., et al. Two-dimensional echocardiographic assessment of left ventricular stroke volume: experimental correlation with thermodilution and cineangiography in normal and ischemic states. Cathet Cardiovasc Diagn 1981, 7(3):247-258.
13. Pacher P., Nagayama T., Mukhopadhyay P., Batkai S., Kass D.A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008, 3(9):1422-1434.
14. Saha J.K., Xia J., Grondin J.M., Engle S.K., Jakubowski J.A. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Exp Biol Med 2005, 230(10):777-784.
15. Sato N., Kobayashi K., Inoguchi T., Sonoda N., Imamura M., Sekiguchi N., et al. Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 2005, 146(1):273-279.
16. Satoh H., Nguyen M.T., Miles P.D., Imamura T., Usui I., Olefsky J.M. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 2004, 114(2):224-231.
17. Vandecaetsbeek I., Raeymaekers L., Wuytack F., Vangheluwe P. Factors controlling the activity of the SERCA2a pump in the normal and failing heart. Biofactors 2009, 35(6):484-499.
18. Maejima Y., Kuroda J., Matsushima S., Ago T., Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011, 50(3):408-416.
19. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002, 34(4):379-388.
20. Murdoch C.E., Zhang M., Cave A.C., Shah A.M. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006, 71(2):208-215.
21. Byrne J.A., Grieve D.J., Bendall J.K., Li J.M., Gove C., Lambeth J.D., et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003, 93(9):802-805.
22. Heymes C., Bendall J.K., Ratajczak P., Cave A.C., Samuel J.L., Hasenfuss G., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003, 41(12):2164-2171.
23. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174(9):5789-5795.
24. Nagaev I., Bokarewa M., Tarkowski A., Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006, 1:e31.
25. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005, 334(4):1092-1101.
26. Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005, 97(9):900-907.
27. Siwik D.A., Pagano P.J., Colucci W.S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol 2001, 280(1):C53-C60.
28. Dobrin J.S., Lebeche D. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert Rev Cardiovasc Ther 2010, 8(3):373-391.
29. Harmancey R., Taegtmeyer H. The complexities of diabetic cardiomyopathy: lessons from patients and animal models. Curr Diab Rep 2008, 8(3):243-248.
30. Hayata N., Fujio Y., Yamamoto Y., Iwakura T., Obana M., Takai M., et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008, 370(2):274-278.
31. Panek A.N., Posch M.G., Alenina N., Ghadge S.K., Erdmann B., Popova E., et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One 2009, 4(8):e6743.
32. Aragno M., Mastrocola R., Medana C., Catalano M.G., Vercellinatto I., Danni O., et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 2006, 147(12):5967-5974.
33. Yoon P.O., Lee M.A., Cha H., Jeong M.H., Kim J., Jang S.P., et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol 2010, 49(2):294-303.
34. Westermann D., Van Linthout S., Dhayat S., Dhayat N., Schmidt A., Noutsias M., et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2007, 102(6):500-507.
35. Ares-Carrasco S., Picatoste B., Benito-Martin A., Zubiri I., Sanz A.B., Sanchez-Nino M.D., et al. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Am J Physiol Heart Circ Physiol 2009, 297(6):H2109-H2119.
36. Choi K.M., Zhong Y., Hoit B.D., Grupp I.L., Hahn H., Dilly K.W., et al. Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 2002, 283(4):H1398-H1408.
37. Vafiadaki E., Arvanitis D.A., Pagakis S.N., Papalouka V., Sanoudou D., Kontrogianni-Konstantopoulos A., et al. The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival. Mol Biol Cell 2009, 20(1):306-318.
38. Vafiadaki E., Sanoudou D., Arvanitis D.A., Catino D.H., Kranias E.G., Kontrogianni-Konstantopoulos A. Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J Mol Biol 2007, 367(1):65-79.
39. Pinton P., Giorgi C., Siviero R., Zecchini E., Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 2008, 27(50):6407-6418.
40. Lee Y., Gustafsson A.B. Role of apoptosis in cardiovascular disease. Apoptosis 2009, 14(4):536-548.
41. Chen C., Jiang J., Lu J.M., Chai H., Wang X., Lin P.H., et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010, 299(1):H193-H201.
42. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108(6):736-740.
43. Umar S., van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010, 333(1-2):191-201.
44. +-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006, 49(6):1434-1446.